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Background: There is little information about predictive ability of haemoglobin A1c (HbA1c) for cardiovascular
disease (CVD) in Asians. To investigate the discriminatory ability of HbA1c to identify subjects who are at greater risk
of developing CVD in a prospective study of a defined community-dwelling Japanese population.
Methods: A total of 2,851 subjects aged 40–79 years were stratified into five groups (HbA1c levels with ≤ 5.0, 5.1–5.4,
5.5–6.4, and ≥ 6.5% and a group with antidiabetic medication) and followed up prospectively for 7 years (2002–2009).
Results: During the follow-up, 119 subjects developed CVD. The multivariable-adjusted risk of CVD was significantly
increased in subjects with HbA1c levels of 5.5–6.4 and ≥ 6.5% and diabetic medication compared to HbA1c level
with ≤ 5.0% (hazard ratio, 2.26 [95% confidence interval, 1.29–3.95] for the 5.5–6.4%; 4.43 [2.09–9.37] for the ≥ 6.5%;
and 5.15 [2.65–10.0] for the antidiabetic medication group). With regard to CVD subtype, the positive associations
between HbA1c levels and the risk of coronary heart disease (CHD) and ischaemic stroke were also significant, but
no such associations were seen for haemorrhagic stroke. The C statistic for developing CVD was significantly
increased by adding HbA1c values to the model including other risk factors (0.789 vs. 0762, p = 0.006), and the net
reclassification improvement was 0.105 (p = 0.004).
Conclusions: Our findings suggest that elevated HbA1c levels are an independent risk factor for CVD, especially
CHD and ischaemic stroke, and that the addition of HbA1c to the model with traditional risk factors significantly
improves the predictive ability of CVD.
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Prior epidemiological studies have established that hyper-
glycaemia is a significant risk factor for the development
of cardiovascular disease (CVD), including coronary heart
disease (CHD) and stroke [1-3]. Various laboratory data
are now used as indicators of hyperglycaemia, mainly in-
cluding fasting plasma glucose and 2-hour postload glu-
cose by a 75 g oral glucose tolerance test. The latter,
however, is considered an expensive, complex, time-
consuming method that burdens subjects with a high load.* Correspondence: fumikeda@envmed.med.kyushu-u.ac.jp
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reproduction in any medium, provided the orIn contrast, haemoglobin A1c (HbA1c) is also widely used
as a marker of average blood glucose concentrations over
the preceding 2 to 3 months and has two advantages over
glucose tests: it does not require subjects to fast [4], and
its intraindividual variability is smaller than that of glucose
measurements [5]. This background, and the basis of the
association of HbA1c with diabetic retinopathy, have led
the American Diabetes Association (ADA) to adopt the
HbA1c level of ≥6.5% as a diagnostic criterion of diabetes
[4]. However, it should be fully verified whether or not
HbA1c can predict macrovascular complications. Several
population-based cohort studies from Western countries
have investigated the association between HbA1c and the
risk of CVDs [6-11], while only a few studies from Asia
have examined this issue [12-14]. Moreover, there is littletd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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other potential risk factors improves the ability to pre-
dict CVD [2,11,15].
The purposes of the present study were to address the
associations between HbA1c levels and the development
of CVD, and to investigate the discriminatory ability of
HbA1c to identify subjects who are at greater risk of devel-
oping CVD in a prospective study of a defined community-
dwelling Japanese population.Methods
Study population and follow-up survey
A population-based prospective study of CVD and ma-
lignancy has been under way since 1961 in the town of
Hisayama, a suburb of the Fukuoka metropolitan area of
Kyushu Island in southern Japan. A detailed description
of this survey was published previously [16]. In 2002, of
a total 3,896 residents aged 40 to 79 years on the town
registry, 3,000 (participation rate, 77.0%) consented to
participate in the examination and underwent a compre-
hensive assessment for the present study. Among these,
146 who had a history of stroke or CHD based on ques-
tionnaires and medical records were excluded, as were 3
others whose HbA1c levels were not measured. The
remaining 2,851 subjects (1,223 men and 1,628 women,
mean age 58.8 years) were enrolled in the study.
The subjects were followed prospectively for 7 years
from 2002 to 2009 by repeated health examinations. The
health status was checked yearly by mail or telephone if
subjects did not undergo a regular examination or had
moved from town. We also established a daily monitor-
ing system among the study team, local physicians, and
members of the town’s Health and Welfare Office. Using
this system, we gathered information on new CVD events,
including suspected cases. When stroke or CHD occurred
or was suspected, physicians in the study team examined
the subject and evaluated his or her detailed clinical infor-
mation. In addition, when a subject died, an autopsy was
performed at the Departments of Pathology of Kyushu
University. During the follow-up period, none of the sub-
jects were lost to follow-up, and 144 subjects died, of
whom 95 (66.0%) underwent autopsy.Clinical evaluation and laboratory measurements
At the baseline examination, HbA1c was measured by
latex aggregation immunoassay using Determiner HbA1C
(Kyowa Medix, Tokyo, Japan). The value for HbA1c was
estimated as a National Glycohemoglobin Standardization
Program equivalent value calculated with the formula
[17]: HbA1c (%) = 1.02 ×HbA1c (Japan Diabetes Society)
(%) + 0.25%. The 75 g oral glucose tolerance test was per-
formed for 2,412 subjects in a fasting state. Plasma glucose
levels were determined by a glucose-oxidase method.Total and high-density lipoprotein (HDL) cholesterol con-
centrations were measured by an enzymatic autoanalyzer.
Blood pressure was obtained three times using an
automated sphygmomanometer (BP-203RV III; Colin,
Tokyo, Japan) with the subject in a sitting position after
resting for at least 5 minutes. The mean value of the
three measurements was used for the analysis. Hyperten-
sion was defined as blood pressure ≥140/90 mmHg and/
or current use of antihypertensive agents. Height and
weight were measured with the subject in light clothes
without shoes, and body mass index (BMI) was calcu-
lated (kg/m2). Electrocardiogram (ECG) abnormalities
were defined as left ventricular hypertrophy (Minnesota
Code 3–1), ST depression (4–1, 2, 3), or atrial fibrillation
(8–3). Each participant completed a self-administered
questionnaire covering lifestyles, medical histories in-
cluding antidiabetic treatment. Smoking habits and alco-
hol intake were classified as either current use or not.
Subjects engaging in sports or other forms of exercise
≥3 times a week during their leisure time were included
in the physically active group.Definition of cardiovascular events
CVD was defined as a first-ever occurrence of CHD or
stroke. The criteria for a diagnosis of CHD included
acute myocardial infarction, silent myocardial infarction,
sudden cardiac death within 1 hour after the onset of
acute illness, and coronary artery disease treated by cor-
onary artery bypass surgery or angioplasty. Acute myo-
cardial infarction was diagnosed when a subject met at
least two of the following criteria: (1) typical symptoms,
including prolonged severe anterior chest pain; (2)
evolving diagnostic electrocardiographic changes; (3)
cardiac enzyme levels more than twice the upper limit of
normal range; (4) morphological changes, including local
asynergy of cardiac wall motion on echocardiography,
persistent perfusion defect on cardiac scintigraphy, or
myocardial necrosis or scars ≥1 cm long accompanied
by coronary atherosclerosis at autopsy. Silent myocardial
infarction was diagnosed for participants who had no
historical indication of clinical symptoms or abnormal
cardiac enzyme changes according to either of two cri-
teria: (1) New onset of abnormal Q waves on ECG plus
morphological myocardium changes (local asynergy on
echocardiography or persistent perfusion defect on scin-
tigraphy), or (2) myocardial necrosis or scars ≥1 cm long
accompanied by coronary atherosclerosis at autopsy.
Stroke was defined as a sudden onset of nonconvulsive
and focal neurological deficit persisting for ≥24 hours.
The diagnosis and classification of stroke were deter-
mined on the basis of clinical information, including
brain CT/MRI or autopsy findings. Stroke was classified
as either ischaemic or haemorrhagic.
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We classified all of the subjects into 5 groups on the basis
of baseline information on antidiabetic medication and
HbA1c levels. We first divided the subjects into 2 groups
according to use of antidiabetic medication. Among the
subjects without antidiabetic medication, those with
HbA1c levels of ≥6.5% were considered as a group having
diabetes according to the ADA guidelines, and those with
levels of <6.5% were further divided into tertiles by HbA1c
levels (≤5.0, 5.1–5.4, and 5.5–6.4%). The incidence of
CVD and its subtypes was calculated by the person–year
method and adjusted for age and sex by the direct method
using 10-year age groupings of the overall study popula-
tion. The age- and sex- and multivariable-adjusted hazard
ratios (HRs) and their 95% confidence intervals (CIs) were
estimated using the Cox proportional hazards model. To
compare the discrimination of incident CVD between the
models adjusted for known CVD risk factors with and
without HbA1c, C statistics analogous to the area under
the receiver operating curve were estimated. The statis-
tical significance of differences was compared using the
method of DeLong et al. [18]. Moreover, the increased dis-
criminatory value of HbA1c levels was further examined
by the net reclassification improvement (NRI) and inte-
grated discrimination improvement (IDI) [19]. The NRI
evaluates changes in estimated prediction probabilities
that imply a change from one category to another between
different models. In this analysis, we classified the prob-
ability of the risk of CVD for 7 years into three categories
of <2.0%, 2.0 to 4.0%, and >4.0%, referring to the medianTable 1 Baseline characteristics of subjects by the haemoglob
HbA1c level (%)
≤ 5.0 5.1–5.4
Variables (n = 955) (n = 92
Age (years) 56 (11) 59 (10)
Men (%) 46.0 38.1
Fasting plasma glucose (mmol/L)* 5.6 (0.5) 5.8 (0.5
2-hour postload glucose (mmol/L)* 6.5 (1.5) 7.1 (1.9
Systolic blood pressure (mmHg) 128 (20) 129 (19
Diastolic blood pressure (mmHg) 77 (12) 78 (12)
Hypertension (%) 33.5 35.8
ECG abnormalities (%) 15.5 12.2
Body mass index (kg/m2) 22.4 (2.9) 23.3 (3.
Total cholesterol (mmol/l) 5.12 (0.90) 5.37 (0.
HDL cholesterol (mmol/l) 1.70 (0.44) 1.62 (0.
Current smoking (%) 27.2 22.0
Current alcohol use (%) 52.7 44.0
Regular exercise (%) 10.6 8.8
Abbreviations: HbA1c, Haemoglobin A1c; ECG, Electrocardiogram; HDL, High-density
All values are given as means (SD) or as percentages.
*These parameters were measured in only 2,412 subjects who underwent a 75 g orvalues of the predicted probabilities among the partici-
pants with and without incident CVD. Continuous NRI
values were also estimated using the predicted proba-
bilities taken as continuous variables. The IDI considers
differences in discrimination slopes between different
models, where the discrimination slope was defined as the
difference between the mean of the estimated prediction
probabilities taken as continuous variables for individuals
with events and the corresponding mean for those with-
out events. The proportions of missing values were less
than 0.1% for all the variables included in the model. A
two-sided p < 0.05 value was considered statistically sig-
nificant in all analyses. Because there was no interaction
between sex and HbA1c levels (data not shown), we in-
cluded men and women together in all analyses. Statistical
analyses were conducted using Statistical Analysis Soft-
ware (SAS) version 9.3 (SAS Institute, Cary, NC).
Ethical considerations
The study protocol was approved by the Kyushu Univer-
sity Institutional Review Board for Clinical Research, and
the procedures followed were in accordance with national
guidelines. All participants provided written informed
consent.
Results
Table 1 compares the mean values or frequencies of pos-
sible risk factors for CVD among the HbA1c levels and
antidiabetic medication. The mean values of age, systolic
and diastolic blood pressures, BMI, and total cholesterolin A1c levels and group with antidiabetic medication
Antidiabetic
medication5.5–6.4 ≤ 6.5
3) (n = 736) (n = 104) (n = 133)
61 (10) 60 (10) 65 (9)
41.9 47.1 56.4
) 6.2 (0.8) 9.2 (2.6) 8.7 (2.0)
) 8.6 (3.1) 16.9 (5.3) 17.1 (4.7)
) 135 (21) 143 (22) 139 (22)
80 (12) 84 (13) 81 (12)
49.3 54.8 69.9
17.7 18.3 14.3
2) 24.0 (3.6) 25.8 (4.3) 23.8 (3.4)
90) 5.41 (0.94) 5.62 (0.91) 5.29 (0.94)





al glucose tolerance test.
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creasing HbA1c levels, whereas the mean HDL cholesterol
values and frequencies of smoking habits and alcohol in-
take decreased. The frequencies of men, ECG abnormal-
ities, and regular exercise did not differ across HbA1c
levels. The subjects with antidiabetic medication had
higher mean (± SD) HbA1c (7.3 ± 1.4%) than the rest of
the study subjects (5.3 ± 0.7%). The former were older,
and had higher frequencies of men and hypertension.
During the 7-year follow-up, we identified 119 first-ever
CVD events (75 men and 44 women). Of these, there were
48 CHD events (37 men and 11 women; 29 acute myocar-
dial infarction, 4 silent myocardial infarction, 3 sudden
cardiac death within 1 hour after the onset of acute illness,
and 12 coronary artery disease treated by coronary artery
bypass surgery or angioplasty), 46 ischemic stroke events
(24 men and 22 women), and 29 haemorrhagic stroke
events (17 men and 12 women). Figure 1 shows theFigure 1 Age- and sex-adjusted incidence of cardiovascular disease b
Abbreviations: HbA1c, haemoglobin A1c. * p < 0.05, ** p < 0.01 vs. HbA1c 5age- and sex-adjusted incidence of CVD and its subtypes
according to the HbA1c levels and antidiabetic medica-
tion. The incidence of total CVD increased significantly
with rising HbA1c levels: there were significant differences
between subjects with HbA1c level of ≤5.0% and those
with HbA1c of 5.5–6.4% or higher (p < 0.01). A similar
pattern was observed for the age- and sex-adjusted inci-
dences of CHD and ischaemic stroke, but no such associ-
ation was seen for haemorrhagic stroke.
As shown in Table 2, these associations were substan-
tially unchanged even after controlling for the confound-
ing factors: age, sex, hypertension, ECG abnormalities,
BMI, total and HDL cholesterol, smoking habit, alcohol
intake, and regular exercise (CVD: HbA1c 5.5–6.4%,
multivariable-adjusted HR = 2.26 [95% CI 1.29–3.95],
p = 0.004; ≥6.5%, HR = 4.43 [95% CI 2.09–9.37], p = <0.001;
CHD: 5.5–6.4%, HR = 2.11 [95% CI 0.90–4.95], p =
0.09; ≥6.5%, HR = 3.55 [95% CI 1.11–11.3], p = 0.03;y haemoglobin A1c levels and antidiabetic medication.
.0%.
Table 2 Adjusted hazard ratios for cardiovascular disease by the haemoglobin A1c level and group with antidiabetic
medication
HbA1c level Antidiabetic
medication≤ 5.0 5.1–5.4 5.5–6.4 ≤ 6.5
No. of subjects at risk 955 923 736 104 133
Total cardiovascular disease (n) 19 31 39 12 18
Age- and sex-adjusted HR (95% CI) 1.00 1.56 (0.88–2.78) 2.19 (1.26–3.81)b 4.94 (2.39–10.2)b 4.53 (2.36–8.69)b
Multivariable-adjusted HR (95% CI) 1.00 1.60 (0.90–2.85) 2.26 (1.29–3.95)b 4.43 (2.09–9.37)b 5.15 (2.65–10.0)b
Coronary heart disease (n) 8 10 17 5 8
Age- and sex-adjusted HR (95% CI) 1.00 1.24 (0.49–3.16) 2.28 (0.98–5.31) 4.63 (1.51–14.2)b 4.30 (1.61–11.5)b
Multivariable-adjusted HR (95% CI) 1.00 1.15 (0.45–2.93) 2.11 (0.90–4.95) 3.55 (1.11–11.3)a 4.39 (1.60–12.0)b
Ischaemic stroke (n) 5 13 15 6 7
Age- and sex-adjusted HR (95% CI) 1.00 2.42 (0.86–6.82) 3.19 (1.15–8.83)a 9.47 (2.88–31.1)b 6.99 (2.18–22.4)b
Multivariable-adjusted HR (95% CI) 1.00 2.57 (0.91–7.29) 3.57 (1.27–10.0)a 9.65 (2.81–33.1)b 8.33 (2.54–27.3)b
Haemorrhagic stroke (n) 6 8 10 2 3
Age- and sex-adjusted HR (95% CI) 1.00 1.26 (0.44–3.66) 1.77 (0.64–4.91) 2.58 (0.52–12.8) 2.38 (0.58–9.66)
Multivariable-adjusted HR (95% CI) 1.00 1.42 (0.48–4.14) 1.87 (0.66–5.25) 2.41 (0.46–12.5) 2.70 (0.65–11.3)
Abbreviations: HbA1c, Haemoglobin A1c; HR, Hazard ratio; CI, Confidence interval.
ap < 0.05, bp < 0.01 vs. Haemoglobin A1c ≤5.0%.
Multivariable adjustment was made for age, sex, hypertension, electrocardiogram abnormalities, body mass index, total and high-density lipoprotein cholesterol
levels, current smoking, current alcohol use, and regular exercise.
Table 3 Reclassification for the absolute risk of
cardiovascular disease development in the Hisayama
study, 2002-2009
Number of subjects who developed cardiovascular disease
Basic model + HbA1c
Basic model <2.0% 2.0–4.0% >4.0% Total
<2.0% 7 3 2 12
2.0–4.0% 2 15 5 22
>4.0% 0 6 79 85
Total 9 24 86 119
Number of subjects who did not develop cardiovascular disease
Basic model + HbA1c
Basic model <2.0% 2.0–4.0% >4.0% Total
<2.0% 1,065 30 5 1,100
2.0–4.0% 170 488 56 714
>4.0% 0 161 756 917
Total 1,235 679 817 2,731
Abbreviations: HbA1c, Haemoglobin A1c.
The basic model included age, sex, hypertension, electrocardiogram
abnormalities, body mass index, total and high-density lipoprotein cholesterol
levels, current smoking, current alcohol use, and regular exercise.
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Finally, to evaluate the impact of HbA1c on the accuracy
of CVD risk assessment, we compared the discriminatory
abilities between models with and without HbA1c. In this
analysis, we included all subjects, because there was no
interaction between use of antidiabetic medication and
HbA1c levels (data not shown). The C statistic for a model
including other potential risk factors, the aforementioned
items, was 0.762, and increased significantly more with the
addition of a continuous HbA1c value (C statistics = 0.789,
p = 0.006). Furthermore, the cross-tabulation for the abso-
lute risk of CVD development between the models with
and without HbA1c values is shown in Table 3. When the
basic model with HbA1c levels was used, 10 subjects were
correctly reclassified into a higher risk category, whereas 8
subjects were inappropriately reclassified into a lower risk
category among subjects who had developed CVD. On the
other hand, 331 subjects were correctly reclassified into a
lower risk category, and 91 subjects were inappropriately
reclassified into a higher risk category among subjects who
had not developed CVD. In addition, the three-category
NRI was estimated as 0.105 (ZNRI =2.87, p = 0.004), the
continuous NRI was 0.356 (ZNRI =3.80, p < 0.001), and the
IDI was calculated as 0.021 (ZIDI = 2.88, p = 0.004).
In addition, in a subgroup analysis we compared the
predictive ability between HbA1c and fasting plasma
glucose or 2-hour postload glucose to identify the indi-
viduals at high risk of future CVD among 2,412 subjects
who had undergone a 75 g oral glucose tolerance test.However, no statistical significance was found between
them (data not shown).
Discussion
In a prospective study of a general Japanese population,
we clearly demonstrated that elevated HbA1c levels,
even in the prediabetic range, were a significant risk
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and ischaemic stroke, in a general Japanese population.
These associations remained robust even after controlling
for comprehensive confounding factors. Furthermore,
adding the HbA1c value to the confounding factors sig-
nificantly improved the predictive ability for total CVD.
These findings are important in that they indicate HbA1c’s
value for predicting the long-term risk of CVD in
Japanese.
Some clinical and population-based cohort studies have
shown that increased HbA1c levels were positively associ-
ated with the risks of CVDs and mortality [6-11,20-25]. In
the present study, the risks of CHD and ischaemic stroke
were significantly or marginally higher even in the subjects
with HbA1c levels of ≥5.5% compared with those with
HbA1c levels of ≤5.0%. There has been controversy over
whether or not the prediabetic levels of HbA1c are associ-
ated with CVD risk. Prior cohort studies in Caucasian
populations have shown positive associations between the
prediabetic range of HbA1c levels and the incidence of
total CVD or CHD [6,7,9,11,26]. A clinical study from
Japan has revealed that HbA1c is significantly associated
with the complexity of coronary lesions even in non-
diabetic adults [27]. Likewise, such an association was
observed for ischaemic stroke in other cohort studies
[8,11,12]. Our findings are in accordance with these
studies. On the other hand, some prospective studies
have demonstrated that the risk of CVD was increased
only in subjects with diabetic levels of HbA1c and not
in those with prediabetic levels [10,13,28]. This incon-
sistency in findings might be caused by differences in
population and methodology among the studies.
Contrary to the studies reporting an association be-
tween HbA1c levels and the risk of CHD or ischaemic
stroke, investigations on haemorrhagic stroke have been
scarce. One prospective study from Japan assessed the
association between HbA1c levels and haemorrhagic
stroke incidence, and found no significant association
[12]. In the present study, the association of HbA1c
levels with the risk of haemorrhagic stroke was also not
significant. These findings suggest that hyperglycaemia
scarcely affects the aetiology of haemorrhagic stroke,
which is generally recognized as the disruption of a ves-
sel wall [29]. However, the number of haemorrhagic
stroke events was limited in these studies. Therefore,
further epidemiological research is required to elucidate
this issue.
To the best of our knowledge, this is the first cohort
study from Asia to demonstrate the predictive ability of
HbA1c to identify persons at high risk of developing
CVD. The Framingham Study showed that the addition
of glycaemic categories did not substantially improve the
ability to predict CVD beyond comprehensive CVD risk
factors alone [2]. However, two recent cohort studiesreported opposite results. The addition of HbA1c to the
Framingham risk score made a small but statistically sig-
nificant improvement to the ability to discriminate CHD
in men in the European Prospective Investigation of
Cancer - Norfolk cohort [15]. The Atherosclerosis Risk
in Communities Study also demonstrated that NRI and
IDI for CHD were significantly improved with the
addition of HbA1c to the model of fasting plasma glu-
cose and other covariates [11]. These findings, when
taken together with ours, indicate it is likely that adding
HbA1c to other comprehensive risk factors will improve
future discriminatory ability for CVD. Since few studies
have investigated this issue, further research is expected.
Why does HbA1c have the potential to predict CVD?
Complex and diverse hypotheses have been proposed to
explain the causal relationship between hyperglycaemia
with atherosclerosis, and one of the important pathways
is recognized as glycosylation. Glycosylation is a non-
enzymatic reaction induced by chronic hyperglycaemia,
and is process in vivo results in two different products:
early and advanced glycation end products (AGEs).
HbA1c is well known as one of the early glycation end
products and is a precursor of AGEs [30,31]. It was re-
ported that AGEs decreased large-vessel elasticity and
induced inflammatory and pro-thrombotic responses in
the vessel wall, thereby being involved in vascular com-
plications [32,33]. Some clinical studies demonstrated
that high AGEs levels were associated with the risk of
CVD [34,35]. Therefore, the biological mechanisms of
glycosylation may be one of the reasons for the relation-
ship between HbA1c and the risk of CVD observed in
our study.
In the present study, the linear association between
HbA1c levels and the risk of incident CVD was observed.
There is a debate as to whether or not the low-normal gly-
caemic state determined by HbA1c is associated with in-
creased CVD risk. At least five studies have shown linearly
increasing risks of CVD with higher HbA1c [2,9,36-38]. In
contrast, other studies showed a U- or J-shaped curve for
the risk of CVD incidence and total or CVD death
[10,11,39,40]. This discrepancy might result from differ-
ences in study design, outcomes, and race or ethnicity.
Further exploration of the health risks associated with
the low-normal glycaemic state derived from HbA1c is
warranted.
The strengths of our study include its longitudinal
population-based design, low selection bias at baseline,
perfect follow-up of subjects, and accuracy of diagnosis
of CVD. However, some limitations of our study should
be discussed. First, HbA1c and other potentially con-
founding factors were based on a single measurement at
baseline, although this limitation is typical of most pro-
spective studies. During the follow-up, risk factor levels
changed due to modifications in lifestyle or medication,
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could have weakened the association found in this study,
biasing the results toward the null hypothesis. Thus, the
true association may be stronger than that shown in our
study. Second, our study included the relatively small
number of event cases of CVD, consisting of stroke and
CHD. The cardiovascular spectrum ranges much further,
including congestive heart failure, transient ischaemic at-
tack, and peripheral artery disease. If the CVD range
would be extended with these diseases, the number of
events would increase, and this would solve the power
issue. Unfortunately, however, we could not include con-
gestive heart failure, transient ischaemic attack, or per-
ipheral artery disease in the endpoints, because we do
not have information on events of these diseases. Last,
our study population was comprised of one ethnic
group, and thus, generalizability to other ethnicities may
be limited. On the other hand, the use of a monoethnic
group in such a study avoids problems relevant to
population stratification artifacts. Further studies in
other ethnic groups will be needed to determine the
applicability of HbA1c levels to the prediction of vascu-
lar events.
Conclusions
A higher level of HbA1c was an independent risk factor
for CVD, especially CHD and ischaemic stroke, in a gen-
eral Japanese population. Moreover, we showed that the
measurement of HbA1c improves the discriminatory
ability of CVD. Further investigations are required to
clarify the association between HbA1c and the type of
CVD, especially in Asian countries where the number of
diabetic individuals has been rapidly increasing.
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